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Abstract
Background: Nitric oxide (NO) is the most powerful vasodilator that inhibits leukocyte adhesion, platelet aggregation,
and vascular smooth muscle cell proliferation. However, excessive NO can cause lipid peroxidation and direct endothelial
cell damage. Therefore, investigation of the role of NO in artherosclerosis development is important. Wen-Xin Decoction
(WXD) has been shown to relieve myocardial ischemia reperfusion injury and prevent leukocyte adhesion and invasion; in
addition, it can accelerate angiogenesis and prevent platelet activation and aggregation. In this study, we focused on the
NO pathway to further clarify the protective effects of WXD on the vascular endothelium in rat models of artherosclerosis.
Methods:Wistar rats were randomly divided into a normal group (n = 10) and a model group (n = 75). Rat models of
atherosclerosis were generated by intraperitoneal vitamin D3 (3 months) injections and administration of a high-fat diet
(3 months with vitamin D3 and 2 months alone). The model rats were randomly divided into five groups (n = 15 each):
model (saline), atorvastatin (4.8 mg/kg/d atorvastatin), high-dose WXD (9 g/kg/d), medium-dose WXD (4.5 g/kg/d), and
low-dose WXD (2.25 g/kg/d) groups. Each group received continuous drug or saline administration (suspended liquid
gavage) for 30 days, following which all animals were sacrificed. The ultrastructure and histopathological changes of
vascular endothelial cells and the expression of PI3K/AKT/eNOS and iNOS in the thoracic aorta tissue were analyzed.
Results: WXD increased NO levels, modulated the NO/ET-1 ratio, and promoted repair of the injured vascular
endothelium in a dose-dependent manner. At a high dose, WXD regulated the NO/ET-1 ratio as effectively as
atorvastatin; furthermore, it increased NO levels within the physiological range to prevent endothelial damage
caused by excessive NO expression. Real-time polymerase chain reaction and Western blot analysis showed
that WXD significantly upregulated the mRNA and protein expressions of PI3K, AKT, and eNOS mRNA and
significantly increased AKT and eNOS phosphorylation.
Conclusions: Our results suggest that WXD protects and maintains the integrity of the vascular endothelium by
activating the PI3K/AKT/eNOS pathway, decreasing iNOS expression, and promoting the release of physiological NO
levels.
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Background
In 2011, the World Health Organization (WHO) re-
ported that cardiovascular disease is the leading cause of
death worldwide, with the number of deaths from cor-
onary heart disease being as high as 730 million. Studies
have shown that the increase in morbidity and mortality
in low- and middle-income countries will increase the
number of worldwide deaths from cardiovascular disease
to 2330 million by 2030 [1]. Therefore, the prevention of
cardiovascular disease is an important topic of research.
Atherosclerosis (AS) is the most common cause of car-
diovascular disease, resulting in insufficient blood supply
to the coronary arteries and subsequent myocardial is-
chemia and hypoxia, which are fundamental pathological
processes of coronary heart disease (CHD). The under-
lying mechanisms are very complex. Studies have been
trying to interpret this disease by investigating various
factors, including “endothelial injury” [2], “lipid infiltra-
tion,” “inflammatory response” [3], and “thrombosis.”
However, it is clear that disruption of the integrity of the
vascular endothelium and its dysfunction are part of the
initial factors causing AS [4–8]. Therefore, the protec-
tion of endothelial function is significant for the preven-
tion and treatment of AS.
Vascular endothelium-dependent systolic and diastolic
function is the gold standard for evaluating endothelial
dysfunction [9]. It is crucial to maintain a balanced nitric
oxide (NO)/ET-1 ratio [10]. Abnormalities in the ET and
NO signaling pathways cause vascular endothelial dys-
function, endothelial necrosis, and disruption of endo-
thelial integrity, all of which will lead to inflammatory
infiltration, thrombosis, plaque formation, and other ser-
ious consequences. NO is a bifunctional endothelial
vasodilator. It is the most powerful vasodilator that in-
hibits leukocyte adhesion, platelet aggregation, and vas-
cular smooth muscle cell proliferation [11]. However,
excessive NO can react with superoxide anions and gen-
erate strong oxidizing peroxynitrite anions (ONOO−),
which can cause lipid peroxidation and direct damage to
endothelial cells. Therefore, it is important to investi-
gate the role of NO in the development of AS. Stud-
ies have shown that the therapeutic effects of statins
and nitroglycerin on CHD are based on the regulation
of NO levels.
In traditional Chinese medicine, the main pathome-
chanism of coronary artery AS and myocardial ischemia
syndrome is Heart-Qi Deficiency (HQD), which is a
leading cause of death and disability worldwide [12].
Wen-Xin Decoction (WXD) is considered an effective
treatment modality that acts by warming yang supple-
menting heart and promoting blood circulation resolving
phlegm (WSPR); this was first recorded in the “Synopsis
of the Golden Chamber,” written and optimized by Pro-
fessor Hongxin Cao (China Academy of Chinese Medical
Sciences, CACMS). WXD is widely used for the amelior-
ation of HQD and the clinical treatment of CHD [13].
As a famous herbal remedy, WXD can significantly re-
lieve coronary artery spasm, decrease plaque formation,
increase the myocardial oxygen supply, and improve the
heart function. A recent metabolomics study showed
that WXD exhibits potential pharmacological effects by
restoring multiple disturbed pathways to the normal
state [14]. Research also confirms that WXD relieves
myocardial ischemia–reperfusion injury through the in-
hibition of NF-κB and downstream ICAM-1 and MCP-1
expression and the prevention of leukocyte adhesion and
invasion. In addition, WXD can accelerate angiogenesis
and prevent platelet activation and aggregation. In this
study, we focused on the NO pathway to further clarify
the protective effects of WXD on the vascular endothe-
lium in rat models of AS.
Methods
Experimental animals
Eighty-five male Wistar rats (5 weeks old; weight, 200 ±
20 g) were provided by the Experimental Animal Center
of the Chinese PLA Military Academy of Medical Sci-
ences [License No.: SCXK-(Army) 2007-004]. The rats
were housed in the experimental animal center at the In-
stitute of Basic Theory, CACMS. There were five rats
per cage, with a total of 17 cages. All rats were provided
free access to water and were maintained on a 12-h
light/dark cycle, with a temperature of 20 ± 2 °C and
humidity of 50 ± 5 %. The animals were cared for in
accordance with the laboratory animal care protocols of
the Institute of Basic Theory of Chinese Medicine,
CACMS. All animal studies conducted here were ap-
proved by the medical ethics committee of the Institute
of Basic Theory of Chinese Medicine, CACMS.
Experimental reagents
The component herbs of WXD included the following:
Ginseng Radix et Rhizoma (10 g), Cinnamomi Ramulus
(10 g), Allii Macrostemonis Bulbus (15 g), Trichosanthis
Fructus (15 g), Pinelliae Rhizoma Praeparatum Cum
Alumine (10 g), Paeoniae Radix Rubra (15 g), Ophiopo-
gonis Radix (15 g), and Coptidis Rhizoma (10 g). These
were purchased from Beijing Tong-Ren-Tang Pharmacy
and were certified as authentic by the Institute of Chinese
Meteria Medica, CACMS. They also fulfilled the standard
requirements of the 2010 version of the Chinese
Pharmacopoeia. The traditional decocting method is de-
scribed as follows. First, 1000 ml water is added for im-
pregnation, the extract is heated for 30 min, and the liquid
is leached. Then, 500 ml water is added to the residue, the
extract is heated for 30 min, and the liquid is leached. The
two portions of leached liquid are merged for liquid static
sedimentation, filtration, and concentration. Finally, the
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derived product is packed for use. For controlled adminis-
tration, we prepared WXD as a dry extract according to
the guidelines of the School of Chinese Materia Medica,
Beijing University of Chinese Medicine. To prepare the
dry extract, the herbs were immersed, boiled, and filtered.
The filtrates were combined and concentrated in a con-
stant volume, steamed in a water bath until nearly dry,
placed in an oven at 105 °C for 3–4 h, and cooled in a
dryer for 0.5 h. concentrate leaching into the powder
preparation. The extract concentration was 30.58 %,
which was equivalent to 3.27 g of the original medicines
per 1 g of dry extract. We used a certain amount of dis-
tilled water to dissolve the dry extract. The dry extract
was prepared in strict compliance with the Chinese
Pharmacopoeia ((see Appendix IO) and CGEP (GMP
herbal extracts) in order to ensure the quality of
medicines.
The other commercial products used in this study
were as follows: atorvastatin calcium (Pfizer, Lipitor;
code number approved by SFDA: J20070061), vitamin D3
(Shanghai General Pharmaceutical Co., Ltd.; code number
approved by SFDA: H31021404; dose: 600,000 IU, 1 ml),
AngII-ELISA kit (BG; E02A0204), ET-1ELISA kit (BG;
E02E0040), NO-ELISA kit (BG; E02N0041), real-time
quantitative polymerase chain reaction (real-time PCR) kit
(SYBR Green PCR Mixture, CWbio. Co., Ltd., CW0957),
rabbit anti-PI3K P85 (4292S; CST; dilution ratio
1:1000), rabbit anti-p-eNOS (9570; CST; dilution ratio
1:1000), rabbit anti-eNOS (ab11627; Abcam; dilution
ratio1:300), rabbit anti-P-AKT (ab38449; Abcam; dilu-
tion ratio 1:500), rabbit anti-AKT (ab8805; Abcam; di-
lution ratio 1:500), rabbit anti-iNOS (ab15323;
Abcam; dilution ratio 1:250), and a high-fat diet (4 %
cholesterol, 10 % lard, 5 % sucrose, 81 % diet).
Preparation of animal models
After 1 week of acclimatization, the Wistar rats were
randomly divided into a normal group (n = 10) and a
model group (n = 75). The total time taken for model
preparation was 5 months. During the first 3 months,
the rats received a high-fat diet combined with intraperi-
toneal injections of vitamin D3 (150,000 U/kg, once a
month). For the next 2 months, they received the high-
fat diet alone.
According to the AS index (AI), the 75 model rats were
randomly divided into five groups of 15 each: model, ator-
vastatin, high-dose WXD, medium-dose WXD, and low-
dose WXD groups. Each group received continuous drug
(suspended liquid gavage) or saline administration for
30 days as follows: normal and model groups, saline
(10 ml/kg/d); atorvastatin group, atorvastatin (4.8 mg/kg/d,
equivalent to five times the adult human dose); WXD
high-dose group, 9 g/kg/d WXD (equivalent to two times
the human dose); WXD medium-dose group, 4.5 g/kg/d
(equivalent to one time the human dose); and WXD low-
dose group, 2.25 g/kg/d (equivalent to half the human
dose). All animals were sacrificed after 30 days of drug or
saline administration, with no food intake before sacrifice.
Tissue preparation
On day 180, rats were anesthetized by intraperitoneal in-
jection of 5 % urethane (1000 mg/kg), following which
blood samples were collected from the abdominal aorta
and the full-length aorta (from the aortic arch to the
iliac artery bifurcation) was harvested. Blood samples
from the abdominal aorta were drawn (10 ml), and the
serum was collected and stored at −20 °C. Serum levels
of cholesterol (CHO), triglyceride (TG), low-density
lipoprotein cholesterol (LDL-C), and high-density lipo-
protein cholesterol (HDL-C) were measured using an
Automatic Biochemistry Analyzer (HICATHI) according
to the manufacturer’s instructions. After removal of the
epicardial adipose tissue, the aortic arch and 1 cm of the
lower end of the thoracic aorta were harvested and
placed in liquid nitrogen for real-time PCR and Western
blot analysis. The coronary artery (1 mm3) was fixed in
glutaraldehyde for observation under a transmission
electron microscope. Part of rat aorta was examined by
hematoxylin and eosin staining for histopathological
changes.
Real-time PCR
Total RNA was extracted by an ultrapure RNA ex-
traction kit. In total, 8-μl RNA samples were used for
1 % agarose gel electrophoresis. Reverse transcription
was performed using the HiFi-MMLV first strand
cDNA synthesis kit (CWbio. Co., Ltd.). RNA tem-
plates (2 μl) were added to a 20-μl reaction system to
achieve a final concentration of 10 ng. Real-time PCR
was performed using the Bioer line-gene quantitative
PCR device, and the products were amplified using
the SYBR PCR Mixture according to the manufac-
turer’s instructions. The primers for AKT, eNOS,
PI3K, actin, and iNOS were as follows: AKT, 5-AGC
ATG GAG TGT GTG GAC AG-3 (forward) and 5-
GAT GAT CCA TGC GGG GCT T-3 (reverse);
eNOS, 5-AAG GCA AAC CAC CCT CTC TG-3 (for-
ward) and 5-TTA GGC TGA CTC CCT CCC AG-3
(reverse); PI3K, 5-GCT CTT TCC CCA GCT GAA
CT-3 (forward) and 5-ACA CAG TGT CGC TGG
TTT GA-3 (reverse); actin, 5-CCC ATC TAT GAG
GGT TAC GC-3 (forward) and 5-TTT AAT GTC
ACG CAC GAT TTC-3 (reverse); and iNOS, 5-
ACACAG TGT CGC TGG TTT GA-3 (forward) and
5-AAC TCT GCT GTT CTC CGT GG-3 (reverse).
The reaction system was as follows: SYBR PCR Mixture
(2×), 10 μl; forward primer (10 uM), 1.5 μl; reverse primer
(10 uM), 1.5 μl; and template, 3 μl. All reactions were
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performed in triplicate. Gene expression was assessed
using the 2−△△CT method as follows: △△CT = △CT (drug
treatment group) − △CT (normal group) and △CT =CT
(target gene) −CT (reference gene).
Western blot analysis
Total protein was isolated using ice-cold RIPA and pro-
tease inhibitor cocktail (Roche); phosphorylated protein
extraction required phosphatase inhibitors. In total,
50 mg of tissues were homogenized using 500 μl of RIPA
lysate buffer, incubated on ice for 20 min, and centri-
fuged at 13,000 rpm (4 °C) for 20 min. The supernatant
was collected and stored at −80 °C. The protein concen-
tration was determined using the BCA Protein Assay Kit
according to the manufacturer’s instructions. Protein
samples (30 μg) were added for 12 % polyacrylamide gel
electrophoresis and transferred to a PVDF membrane.
The membrane was blocked with 5 % skimmed milk at
room temperature for 2 h, incubated with the primary
antibody for 1 h at room temperature, and maintained at
4 °C overnight. The following day, the membrane was
washed with TBST (six times, 5 min each) and incubated
with the secondary antibody at room temperature for
1 h. After washing with TBST (six times, 5 min each),
the membrane was developed in a darkroom. The gray
scale of the protein bands was analyzed using ImageJ
software.
Statistical analysis
All data are expressed as means ± standard deviations
(means ± SDs). Statistically significant differences be-
tween groups were determined using one-way ANOVA
and Dunnett’s t-tests. The results of real-time PCR and
Western blot analysis were analyzed using independent
samples two-tailed t-tests. All data were analyzed using
SPSS 16.0 software. A p-value of <0.05 was considered
statistically significant.
Results
General condition of animals
Before model preparation, all animals were alert, respon-
sive, and healthy. After model preparation, the rats in
the normal group exhibited smooth fur, were supple and
active, and ate well. Compared with the normal group,
the rats in the model group were significantly under-
weight and less active and exhibited dull fur, significantly
lesser food intake, teeth deformation, and nose bleeding.
Compared with the model group, the rats in the WXD-
treated groups ate well, were very active, and exhibited
significant weight gain (Table 1) and smooth fur. Four
rats in the model group and one in the WXD-treated
group died during the experiment. Autopsy revealed that
two of the four rats from the model group and the rat
from the WXD-treated group died because of excessive
anesthesia administered during blood sample collection
from the eye vein on day 120. One rat in the model
group was diagnosed with heart failure according to the
presence of a pale heart, swollen and bleeding lungs, ex-
tremely low weight, and mouth bleeding, while inappro-
priate gavage was identified as the cause of instant death
in the remaining rat.
Effects of WXD treatment on the endothelial cell
ultrastructure
Transmission electron microscopy revealed significant
ultrastructural changes in the endothelial cells, intimal
and medial elastic membranes, and smooth muscle cells
in the aorta from the model group. These included
swelling and protrusion of the endothelial cells, elastic
membrane loss, and branched smooth muscle cells.
After WXD treatments, there was no significant protru-
sion and/or thickening of the thoracic aorta membrane,
with no significant disruption in the integrity of the
endothelial cells, elastic membranes, and smooth muscle
cells. The high-dose WXD group exhibited the best
therapeutic effects. In the atorvastatin group, the endo-
thelial cells were swollen and dislodged, accompanied by
loose connective tissue and disruption of the integrity of
the smooth muscle cell layer. The overall therapeutic ef-
fects were better in the WXD treatment groups than in
the atorvastatin group (Fig. 1).
Effects of WXD treatment on histopathological changes in
the thoracic aorta
Histopathological changes in the rat aorta were exam-
ined by hematoxylin and eosin staining (Fig. 2). Com-
pared with the model group, the WXD and atorvastatin
groups showed a visible decrease in pathological
changes; the vessel walls were slightly rougher and
thicker, and fewer atherosclerotic plaques were observed.
Effects of WXD treatment on serum lipid levels
Compared with those in the model group, CHO, TG,
and LDL-C levels were lower in the medium- and high-
dose WXD groups (p < 0.05), while there was no
Table 1 Changes in the body weight of rats in each group
(mean ± SD, gram)
Group N T0 T1 T2
Normal 10 206.5 ± 8.4 571.3 ± 60.9 582.8 ± 48.2
Model 10 201.1 ± 11.0 500.1 ± 19.2* 435.6 ± 59.3*
L-WXD 10 208.4 ± 15.1 505.6 ± 39.1# 541.8 ± 34.3#
M-WXD 10 207.2 ± 7.8 510.5 ± 33.3# 568.4 ± 39.8#
H-WXD 10 206.6 ± 24.2 508.4 ± 31.8# 630.0 ± 62.4#
Atorvastatin 10 206.3 ± 9.1 500 ± 71.2# 507.1 ± 66.3#
Note: T0, −1 day; T1, 150 days; T2, 180 days
*p < 0.05, versus the normal group
#p < 0.05, versus the model group
Li et al. BMC Complementary and Alternative Medicine  (2016) 16:27 Page 4 of 10
Fig. 1 Changes in the structure and ultrastructure of the aortic arch as observed by transmission electron microscopy (magnification, ×10,000)
after 30 days of treatment with Wen-Xin Decoction (WXD). a normal group; b model group; c low-dose WXD group; d medium-dose WXD group;
e high-dose WXD group; f atorvastatin group
Fig. 2 Effects of Wen-Xin Decoction (WXD) on histopathological changes in the aortic arch after 30 days of treatment (magnification, ×200).
a normal group; b model group; c low-dose WXD group; d medium-dose WXD group; e high-dose WXD group; f atorvastatin group
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significant difference between high-dose WXD group
and atorvastatin group (p > 0.05). HDL-C levels (p <
0.05) were increased in the medium- and high-dose
WXD groups (Table 2).
Effects of WXD treatment on serum NO levels and the
NO/ET-1 ratio
Compared with those in the normal group, serum NO
levels in the model group were significantly decreased,
with the data distributed mostly within the [Mean − 2σ,
Mean] range (p < 0.001; Fig. 3a). Compared with those in
the model group, serum NO levels in the WXD treat-
ment groups were significantly increased in a dose-
dependent manner (p < 0.001, Fig. 3a), with data for the
medium- and low-dose WXD groups distributed mostly
within the [Mean, Mean + 2σ] range, indicating that
WXD treatment significantly increased NO levels within
the physiological range to protect the blood vessels
(Fig. 3a). The atorvastatin group also exhibited a signifi-
cant increase in NO levels compared with the model
group (p < 0.001). However, most of the data exceeded
the [Mean, Mean + 2σ] range; excessive expression of
NO may damage the endothelium.
Compared with that in the normal group, the serum
NO/ET-1 ratio was significantly decreased in the model
group, indicating the dysfunction of diastolic vasocon-
striction. Compared with that in the model group, this
ratio was balanced in the WXD and atorvastatin groups
(p < 0.001); the high-dose WXD group exhibited slightly
greater effects compared with the atorvastatin group
(p > 0.05; Fig. 3b). Although low-dose WXD treatment
increased the NO/ET-1 ratio, there was no significant
difference from the ratio in the model group (p > 0.05),
indicating that the effects of WXD treatment on the
NO/ET-1 ratio was dose dependent.
Effects of WXD treatment on the PI3K/AKT/eNOS pathway
High-dose WXD treatment significantly increased the
protein expression of PI3K and eNOS and signifi-
cantly enhanced the phosphorylation of AKT and
eNOS, indicating an upregulation of the PI3K/AKT/
eNOS pathway. Low-dose WXD treatment only in-
creased AKT phosphorylation and had little impact on the
total protein expression of PI3K, AKT, and eNOS.
Medium-dose WXD treatment increased protein expres-
sion of PI3K and eNOS and phosphorylation of AKT and
eNOS, although it had little impact on AKT expression.
Atorvastatin treatment significantly increased PI3K pro-
tein expression and enhanced AKT and eNOS the phos-
phorylation. iNOS protein expression was downregulated
in all treatment groups; however, the high-dose WXD and
atorvastatin groups exhibited the best therapeutic effects.
This indicated that the effects of WXD were dose
dependent. The images of protein expressions of PI3K,
AKT , p-AKT, eNOS, p-eNOS and iNOS are in Figs. 4a
and 5a, and the results are presented in column diagram
form in Figs. 4b and 5b.
Effects of WXD on the gene expression of PI3K, AKT,
eNOS and iNOS
Compared with those in the normal group, mRNA levels
of PI3K, AKT, and eNOS were significantly decreased in
the model group (Fig. 6), while compared with those in
the model group, these levels were increased in the
high-dose WXD group. The effects of WXD treatment
were dose dependent. Compared to the model group,
high-dose treatment increased PI3K, AKT, and eNOS
mRNA expressions by 27.2 (p < 0.05), 18.8 (p < 0.05), and
14.5 folds (p < 0.05), respectively. Meanwhile, it down-
regulated iNOS mRNA expression by 0.50 folds com-
pared with atorvastatin.
Discussion
The NO level should be within the physiological range
for effective endothelial protective effects; very high or
very levels can cause vascular endothelial damage.
Therefore, we analyzed NO levels and the NO/ET-1 ra-
tio using quality control analysis methods in rat models
of AS in the present study conducted to assess the pro-
tective effects of WXD on the vascular endothelium. We
first obtained Mean ± σ data for the normal group and
defined the normal range values as Mean ± 2σ. Then, we
Table 2 Effects of Wen-Xin Decoction (WXD) treatment on serum lipid levels (mmol/L)
Group N CHO LDL-C TG HDL-C
Normal 10 1.836 ± 0.266 0.314 ± 0.039 1.053 ± 0.142 1.258 ± 0.158
Model 10 3.861 ± 0.841*** 1.436 ± 0.534*** 2.706 ± 1.023*** 0.884 ± 0.121***
L-WXD 10 3.530 ± 0.246△△△ 0.935 ± 0.108###△△ 2.208 ± 0.518△△ 0.952 ± 0.117△△△
M-WXD 10 2.687 ± 0.456# 0.754 ± 0.195### 2.163 ± 0.316△△ 1.094 ± 0.161##△△△
H-WXD 10 2.699 ± 0.488# 0.629 ± 0.131### 1.553 ± 0.236### 1.284 ± 0.255###
Atorvastatin 10 2.462 ± 0.198## 0.595 ± 0.127### 1.430 ± 0.247### 1.496 ± 0.144###
Note: values are expressed as mean ± SD
*p < 0.05,**p < 0.01, ***p < 0.001, versus the normal group
#p < 0.05,##p < 0.01, ###p < 0.001, versus the model group
△△p < 0.01, △△△p < 0.001, versus the atorvastatin group
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compared the values obtained for each group with the
normal value to determine whether the data were within
the normal range. We successfully created a rat model
of AS by intraperitoneal injections of large doses of Vita-
min D3 and the administration of a high-fat diet for 5
consecutive months. This combination resulted in in-
timal damage, deformation and loss of endothelial cells
in the thoracic aorta, a significant decrease in the ex-
pression of serum NO levels, and a balanced NO/ET-1
ratio. WXD treatment significantly decreased the extent
of vascular endothelial damage and promoted the recov-
ery of endothelial cell morphology. These effects may be
attributed to the increase in NO levels within the
physiological range and a balance in the NO/ET-1 ratio.
High-dose WXD exhibited better protective effects com-
pared with atorvastatin.
We further demonstrated that the effects of WXD
treatment on NO expression may be achieved in two
Fig. 3 a Effects of Wen-Xin Decoction (WXD) on serum nitric oxide (NO) levels. b Effects of WXD on the serum NO/ET-1 ratio (n = 10)
Fig. 4 Protein expression of PI3K, AKT, p-AKT, and β-actin in the aorta after 30 days of Wen-Xin Decoction (WXD) treatment. Data are obtained
from six rats. *p < 0.05, **p < 0.01 compared with the normal group. #p < 0.05, ##p < 0.01 compared with the model group, △ p < 0.05 compared
with the atorvastatin group
Li et al. BMC Complementary and Alternative Medicine  (2016) 16:27 Page 7 of 10
ways. First was the promotion of NO expression within
the physiological range through regulation of the PI3K/
AKT pathway and activation of its downstream target
eNOS gene expression. WXD significantly increased the
expression of PI3K, AKT, and eNOS at both gene and
protein levels. Meanwhile, it significantly promoted
eNOS and AKT phosphorylation, which in turn acti-
vated the PI3K/AKT/eNOS pathway to promote NO
expression within the physiological range. Second was a
decrease in iNOS protein expression to inhibit the exces-
sive generation of NO and ET-1. Thus, WXD simultan-
eously increased NO expression within the physiological
range to relax blood vessels and prevent vascular endothe-
lial damage caused by excessive NO production. There-
fore, WXD modulates NO via eNOS and iNOS dual
regulation.
NO synthesis and release is regulated by NOS, in-
cluding eNOS and iNOS. A meta-analysis indicated
that, in endothelial cells, functional eNOS oxidized its
substrate L-arginine to L-citrulline and NO, which is
the main source of NO in endothelial cells. This
mechanism is known as the eNOS/NO synthesis
pathway. When eNOS is activated, it produces NO
that diffuses to vascular smooth muscles and in-
creases intracellular cAMP concentration by activating
soluble guanylate cyclase, thus playing a role in blood
vessel dilation, inhibition of platelet and monocyte
cell adhesion [15], and the maintenance of normal physio-
logical functions of endothelial cells. Studies have
shown that the eNOS activity can be regulated at
both protein expression [16] and gene transcription
levels, including eNOS phosphorylation and the inter-
actions of other active substances [17, 18]. Activation
of the PI3K pathway can enhance eNOS phosphoryl-
ation [19]. Studies have demonstrated that PI3K/AKT
can promote eNOS/NO expression in the cardiovas-
cular system and play a role in the protection of
endothelial function; meanwhile, endothelial dysfunc-
tion is related to inhibition of the PI3K/AKT/eNOS
pathway [20]. The results from this study further con-
firmed that WXD protects the vascular endothelium
via regulation the PI3K/AKT/eNOS pathway.
The pathological process of AS, from the onset of dis-
ease to plaque formation and rupture, develops over the
course of decades. This process involves extremely com-
plex cell signal transduction pathways. A specific path-
way may only be activated in a certain period during the
pathogenesis cycle, and the same pathway activated at
different time points may act like a “double-edged
sword.” The PI3K/AKT pathway is one such pathway in
AS pathogenesis. For example, activation of the PI3K/
AKT pathway can inhibit vascular smooth muscle cell
migration [21], decrease platelet adhesion [22, 23], in-
hibit tissue factor expression, decrease vascular
Fig. 5 Protein expression of eNOS, p-eNOS, iNOS, and β-actin in the aorta after 30 days of Wen-Xin Decoction (WXD) treatment. Data are obtained
from six rats. *p < 0.05, **p < 0.01 compared with the normal group. #p < 0.05, ##p < 0.01 compared with the model group
Fig. 6 Fold-changes in the expression of PI3K, AKT, eNOS, and iNOS mRNA in the thoracic aorta, measured by real-time polymerase chain reaction
(PCR) and calculated by the 2−ΔΔCT method, after treatment with various doses of Wen-Xin Decoction (WXD) for 30 days. Data are obtained from
six rats. *p < 0.05 compared with the normal group. #p < 0.05 compared with the model group
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endothelial cell apoptosis [24, 25], and promote eNOS/
NO expression. On the other hand, activation of PI3K in
macrophages via oxLDL and Ang II can increase macro-
phage activity and enhance the immune inflammatory
response [26, 27]. In the present study, we demonstrated
that WXD can activate the PI3K/AKT/eNOS pathway;
however, the effects of WXD treatment on macrophage
activity remain elusive and will be the focus of our
future research.
Conclusion
In conclusion, our results suggest that WXD protects
and maintains the integrity of the vascular endothelium
by activating the PI3K/AKT/eNOS pathway, decreasing
iNOS expression, and promoting the release of physio-
logical NO levels. Safe and effective treatment of CHD
remains a worldwide problem. Classic thrombolytic ther-
apy or modern bypass techniques fail to decrease the
mortality from CHD. Chinese medicine has been clinic-
ally used for more than 1000 years and has been proven
to be safe and effective. The effects of WXD on the
treatment of CHD have been studied for nearly 30 years
by Professor Cao Hongxin. In the present study, we fur-
ther demonstrate that WXD increases the physiological
NO levels to protect the vascular endothelium in AS, thus
providing a possible alternative for the treatment of CHD.
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